Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease
about
Experimental therapies and ongoing clinical trials to slow down progression of ADPKDUrinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric studyUrine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.Pathophysiology of copeptin in kidney disease and hypertensionThe importance of total kidney volume in evaluating progression of polycystic kidney diseaseDoes increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patientsPredictors of autosomal dominant polycystic kidney disease progressionPotentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study.Identification of Biomarkers for PKD1 Using Urinary Exosomes.Serum copeptin as a new biomarker in the early diagnosis of decline in renal function of type 2 diabetes mellitus patientsVasopressin and disruption of calcium signalling in polycystic kidney disease.Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohortChronic recurrent dehydration associated with periodic water intake exacerbates hypertension and promotes renal damage in male spontaneously hypertensive rats.Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.Copeptin and its potential role in diagnosis and prognosis of various diseases.Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease.Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment.Vasopressin: a novel target for the prevention and retardation of kidney disease?Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials.Diagnostic Evaluation as a Biomarker in Patients with ADPKD.Insights into autosomal dominant polycystic kidney disease by quantitative mass spectrometry-based proteomics.Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?New treatment paradigms for ADPKD: moving towards precision medicine.Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
P2860
Q27001230-1C49348C-CA19-4074-B48F-62634A6780CEQ28484968-1B39DE69-A327-46BB-A741-C84138F1A3F7Q31154416-EE72FE09-4238-419C-BC9A-B68BA8C9AD15Q33660700-37249868-E621-41E7-A3E8-7C09ED1783A6Q33792317-6268D2A5-71B2-4FEE-9CCD-F1B47AB65D16Q33873107-EFDAB018-915D-487F-B03E-A2BDE04911D1Q34094366-064503BC-7319-4FF2-98B2-CC6DFD348792Q34124758-07A16C70-64EB-446B-94F4-90801D258C5FQ34427678-6F7B2B4C-B7D5-4A25-B4CE-2D32A1E89C1AQ34858052-40E443EF-30B2-471C-9BD9-BAEBBB312CFFQ35658585-2AD9C434-9BF5-4339-8D6B-068C8C1F276FQ35790549-79C55BCF-FB0D-4058-806D-F7445F27A7EBQ35958749-FC3D0916-2A56-42C4-BA3C-BCFEDDCC6E99Q35962991-F62CCD14-E2ED-4F0E-9CDC-2967E5292F7BQ36616057-55AB3E53-CD34-4F66-8B06-4A1D3715FD53Q37274293-E3439FD7-76B0-4F7D-8F11-FB20CB6C4601Q37278044-447D2866-97DA-43E9-ABC8-2FD457708BE3Q37508425-201A6A17-D6C3-474F-89B8-EA3D788F9542Q37630699-44B6F86A-77FD-4DDE-9BEF-351E501E5E5CQ37723395-D701504F-1A40-4706-A683-731CFC8306B3Q37892306-9AF82383-AE91-4DAC-8C59-AE44876E9A1CQ38030726-F0EBF369-C4C8-4EBB-B53B-3D1DF4E56FE7Q38084471-F6D165E7-05EA-451F-8551-6EE2E7C09F8AQ38181599-660DBD53-726D-4E25-8666-F45289EBA6A8Q38978474-A066A85D-AA7A-4486-BA27-D083A5F02A9EQ39255681-43B73CD3-7EE9-4D1E-B7B7-30BC6BA41303Q48216298-F4E4D42C-9926-49F4-B485-4185AF0CEEA4Q49494721-69541FCA-CC18-41C7-800A-2419A5E408C4Q52850208-4F7A5CE1-FC09-4C5A-807E-B6F11C8A3A3BQ53603650-FB829114-C655-468F-A4BC-3B445C34D3F3
P2860
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@ast
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@en
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@nl
type
label
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@ast
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@en
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@nl
prefLabel
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@ast
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@en
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@nl
P2093
P2860
P356
P1476
Copeptin, a surrogate marker o ...... nant polycystic kidney disease
@en
P2093
Eric J van der Jagt
Esther Meijer
Gerjan Navis
Joachim Struck
Paul E de Jong
Ron T Gansevoort
Stephan J L Bakker
P2860
P304
P356
10.2215/CJN.04560510
P577
2010-10-07T00:00:00Z